Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Carbohydr Polym ; 297: 120007, 2022 Dec 01.
Artigo em Inglês | MEDLINE | ID: mdl-36184135

RESUMO

According to the global mapping of dry eye disease (DED), nearly 5 to 50 % of people suffer from DED, and this number is on the rise. The drug of choice Cyclosporine A (CsA) exhibits poor ocular bioavailability due to high molecular weight and lipophilicity. Moreover, formulations of CsA currently available are in the form of oil-based emulsions that are known to cause ocular irritation and pain. In this study, sulfobutylether-ß-cyclodextrin (SBE-ß-CD) based binary and ternary supramolecular complexes of CsA were developed as completely oil-free, and particle-free eye drops to treat DED. The physicochemical characterizations were supplemented with relevant in silico studies, to ascertain the findings. Further, the efficacy of the complexes was evaluated in the scopolamine-induced mouse model of DED. The complexation improved the CsA solubility by ~21-fold, with ~4-fold improvement in dissolution and transcorneal permeation. The non-irritancy and non-toxicity were confirmed by hen's egg chorioallantoic membrane assay and cytotoxicity assay using human corneal epithelial cells, respectively. The in vivo treatment with the ternary CD complex demonstrated better management of the dry eye supported by the tear volume assessment, corneal fluorescein staining, and histopathological studies of the cornea, lacrimal gland, and harderian gland. The study demonstrates the potential of the supramolecular complex as an alternative to the oil-based formulation of eye drops for drugs that show low solubility and poor corneal permeation.


Assuntos
Ciclodextrinas , Síndromes do Olho Seco , Animais , Galinhas , Córnea , Ciclosporina/química , Ciclosporina/farmacologia , Ciclosporina/uso terapêutico , Síndromes do Olho Seco/tratamento farmacológico , Feminino , Fluoresceína , Humanos , Camundongos , Soluções Oftálmicas/farmacologia , Soluções Oftálmicas/uso terapêutico , Derivados da Escopolamina/uso terapêutico
2.
J Control Release ; 330: 257-283, 2021 02 10.
Artigo em Inglês | MEDLINE | ID: mdl-33345832

RESUMO

In recent years, there have been significant advancements in the nanotechnology for cancer therapy. Even though molybdenum disulphide (MoS2)-based nanocomposites demonstrated extensive applications in biosensing, bioimaging, phototherapy, the review article focusing on MoS2 nanocomposite platform has not been accounted for yet. The review summarizes recent strategies on design and fabrication of MoS2-based nanocomposites and their modulated properties in cancer treatment. The review also discussed several therapeutic strategies (photothermal, photodynamic, immunotherapy, gene therapy and chemotherapy) and their combinations for efficient cancer therapy along with certain case studies. The review also inculcates various diagnostic techniques viz. magnetic resonance imaging, computed tomography, photoacoustic imaging and fluorescence imaging for diagnosis of cancer.


Assuntos
Nanocompostos , Neoplasias , Dissulfetos , Humanos , Imunoterapia , Molibdênio , Neoplasias/diagnóstico por imagem , Neoplasias/terapia , Fototerapia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA